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Abstract 
The ion beam laboratory ISL at the Hahn-Meitner-
Institut Berlin (HMI) supplied light and heavy ion beams 
for research and applications in solid state physics, 
industry, and medicine. Since 1998, eye tumours are 
treated with 68 MeV protons in collaboration with the 
University Hospital Benjamin Franklin, now Charité - 
Campus Benjamin Franklin. In autumn 2004 the board of 
directors of the HMI decided to close down ISL at the end 
of 2006. In December 2006, a cooperation contract 
between the Charité and the HMI was signed to assure the 
continuity of the eye tumour therapy, at this moment 
being the only facility in Germany.  
The accelerator operation, continued with reduced man-
power, required changes in the set-up of the accelerators. 
A new, facile injector for protons is under commissioning. 
Increasing the reliability will be a key issue.  
The last two years of operation of ISL as a full multi-
purpose accelerator will be shown and examples of the 
research work will be demonstrated. The conversion of a 
multi-ion, variable energy accelerator to a dedicated 
accelerator for eye tumour therapy will be discussed. 
ION BEAM LABORATORY ISL 
Accelerator Layout 
 
Figure 1: Layout of the ISL facility, consisting of a k=132 
isochronous cyclotron served by two injectors: a Van-de-
Graaff accelerator for light ions and a frequency variable 
RFQ with two ECR-sources for heavy ions. 
The mission of the ion beam laboratory 
(Ionenstrahllabor) ISL was the provision of fast ions for 
solid state physics, materials analysis and medical 
applications in basic as well as applied research. For this 
purpose, ISL operated an accelerator complex serving 
nearly 20 target stations (see fig. 1). The properties of the 
ISL beams – energy range, ion species, beam emittance, 
pulse structure, and stability – was unique and allowed a 
vast variety of experiments. 
Accelerator Operation 
With the available manpower, about 4500 hours of 
beam time were scheduled each year (see fig. 2). Since 
2003, always more than 3200 hours of beam on target 
could be achieved. The all-time high in 2006 was due to a 
complete stop of all R&D activities as well as the full 
operation of the second ECR ion source of the RFQ, 
leading to shorter tuning times: One source could be 
tuned, e.g. for a gold beam, while the other one was still 
delivering beam to the experiment. Gold ions were 
employed to about 30% of the beam time for materials 
modification and materials analysis, whereas for 25% of 
the beam time protons were used for medical purposes 
and materials analysis. Other ions used comprised D, rare 
gases, Cu, and so-called cocktail beams. The short beam 
times needed for solid state physics – typically a few 
shifts only – and the often requested changes in ion 
species and energy lead to the high tuning times. Beam 
time losses due to break-downs over the last years of ISL 
amounted to 5%. 
 
Figure 2: Operation statistics of ISL (1995-2006) and the 
HZB cyclotron for medical purposes only. 
Experiments 
Experiments were carried out at 15 high-energy target 
stations. The focus of the research at ISL was solid state 
physics: About 50% of the beam time was used for 
materials modifications and ion-solid interactions, e.g. the 
study of nanoscale self-assembly of thin oxide films 
under fast heavy ion irradiation [1]. The dedicated target 
stations for this research topic included, among others, 
on-line XRD spectrometer for the observation of ion 
induced structural changes, in-situ electron spectroscopy, 
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and the spectroscopy of desorbed neutral atoms by laser 
ionisation. A stripper behind the cyclotron permitted the 
selection of the mean equilibrium charge state [2]. In 
cooperation with industry, polymer foils were irradiated 
with heavy ions for ion track filter production.  
Materials analysis obtained 15% of the beam time. 
With Elastic Recoil Detection Analysis (ERDA), about 
400 samples each year were analysed, mainly for 
semiconductor and photovoltaic device-developments by 
measuring the depth-dependent concentration from 
hydrogen to heavy elements up to a depth of about 3 µm 
[3]. The heavy ion ERDA set-up at ISL provided a 
flexible tool for the investigation of a broad variety of 
analytical questions, which was unique in Germany. 
High-energy Proton Induced X-ray Emission (PIXE) was 
applied to objects d’art and archaeological items. The 
advantage of high-energy PIXE is the possibility to 
measure heavy elements behind thick layers of material 
non-destructively. More than 2000 samples have been 
analysed for museums, mainly from Berlin/Brandenburg, 
but also from all over Europe, e.g. medieval silver coins 
from Austria [4].  
High-energy protons as well as cocktail beams, e.g. 
6MeV/u 12C3+, 16O4+, 36Ar9+, 86Kr21+, 132Xe33+, were used 
for radiation hardness testing. The tested devices ranged 
from electronic components to solar cells for space 
applications [5].  
Since 1998, eye tumours are treated in cooperation with 
the Charité, Universitätsmedizin Berlin, Campus 
Benjamin Franklin. In the midterm evaluation report the 
review committee stated: “The review committee 
considers the quality of research and development 
performed during the reporting period as excellent. In 
terms of the dosimetric precision achieved, the group has 
surpassed other groups from which they have learnt (PSI 
and MGH) and is currently in a leading position world-
wide.” However, the directors decided on the basis of the 
shutdown of ISL to stop the participation within the 
programme oriented funding topic “Health”. The 
excellent performance both in therapy and in associated 
research initiated a solution to continue the eye tumour 
therapy as described below. 
CONVERSION TO A DEDICATED 
MEDICAL ACCELERATOR 
In order to ensure the continuation of the eye tumour 
therapy – Germany’s first and, up to now, only therapy 
centre for eye tumours – a cooperation contract was 
signed between the Hahn-Meitner-Institut and the Charité 
in December 2006. The department “protons for therapy” 
now supplies the proton beam for the Charité. The 
financial circumstances lead to a reduction of the man-
power for accelerator operation to a third of the original 
crew. Therefore, the accelerator operation was changed 
from a three-shift to a two-shift mode. Over night the 
machine idles, monitored by new control programmes. 
The high-energy target stations have been disconnected 
from the cyclotron and the control system was reduced to 
the remaining components. The RFQ was removed as it 
cannot provide protons.  
The injector for light ions, the Van-de-Graaff, provided 
reliably over more than 30 years a wide variety of ion 
species over a broad energy range. However, the source 
on the high-voltage terminal including a RF bunching 
system, the moving belt, and the elaborated fast high-
voltage regulation system require careful maintenance. To 
reduce the required manpower, a 2 MV tandetron 
accelerator was bought from the Bundesanstalt für 
Materialforschung und -prüfung (Federal Institute for 
Materials Research and Testing). It was installed in the 
cyclotron vault, were the RFQ was originally situated. 
Thus, the installation of the tandetron could be executed 
without interruptions of the therapy schedule. In addition, 
this position will reduce the length of the injection line by 
more than 20 m. As the beam tests of the tandetron-
cyclotron combination have been successful, the permit to 
use it for patient treatment will be applied for. 
The tests performed for the dual shift operation as well 
as the beam tests with the tandetron account for the high 
number of beam tests hours as can be seen in fig. 2. 
DEDICATED OPERATION FOR 
MEDICAL PURPOSES 
In spite of the decreased manpower, operation 
continued smoothly. The reliability of the machine was 
very high: Beam time losses due to break-downs were 
between 2% and 5% – the latter was caused by one major 
failure, an internal water leak in the RF system of the 
cyclotron. This lead, for the first time since 1998, to an 
interruption of the therapy week. The small number of 
scheduled beam time hours results in huge effects on the 
beam statistics by single major breakdowns. The increase 
of beam time as shown in fig. 2 in the past two years is 
due to an increasing patient number. 
 
Figure 3: Patient figures treated per years (bars) and in 
total (white numbers). 
In 2007, eleven therapy weeks were scheduled: 
Monday is reserved for quality assurance; patients receive 
their irradiation in four fractions from Tuesday to Friday. 
As can be seen in fig. 3, the number of patients rose to 
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more than 210 per year. Hence, the number of therapy 
weeks was increased to twelve. Nearly 90% of the 
indications are choroidal melanomas. The case-subgroup 
of large uveal melanomas increased, mostly followed by 
surgical removal (endoresection or transscleral resection) 
of the inactivated tumour mass to prevent toxic reactions.  
Special Patients: Children - 7 months to 5 years  
With its high local control rates of about 95% and high 
dose conformation proton therapy is a very powerful tool 
in the treatment of ocular tumours. Generally, to achieve 
these results the cooperation of the patient is absolutely 
necessary. Small children are unable to cooperate in the 
appropriate way; therefore, they must be treated under 
general anaesthesia. To prepare the treatment room for the 
therapy of anaesthetized children a mobile anaesthesia 
workstation was installed. Car seats, for different body 
sizes, were modified to fit to the treatment chair. 
The anaesthesia procedure takes place on a separate 
couch for anaesthesia in the treatment room. Under 
general anaesthesia the child is transferred into one of the 
modified car seats. Within the seat the child is still in a 
lying position, the body is fixed by seat belts. A 
thermoplastic mask fixed at the car seat immobilizes the 
head. The car seat with the child is then mounted at the 
treatment chair and moved into a nearly sitting position. 
In treatment position the eyelids are moved out of the 
irradiation field by lid retractors. A suction cup is attached 
to the cornea to adjust the gazing angle of the eye for 
treatment (see fig. 4). After verification of the localization 
the irradiation takes place. The position of the eye and the 
vital signs are continuously monitored in the treatment 
and in the control room.  
 
Figure 4: One of the children in treatment position. 
Following treatment the child is transferred to the 
couch for recovery from anaesthesia. As soon as the child 
can breathe by itself and has protective reflexes, it is 
transferred to a recovery room for observation until an 
ambulance transports the patient back to the eye hospital. 
Prior to the treatment course a simulation session with the 
child under general anaesthesia is necessary to fit the 
mmobilization mask and test the feasibility of the 
treatment plan. The treatment procedure itself takes about 
two hours: one hour for anaesthesia and positioning, one 
minute irradiation, few minutes dismounting and roughly 
45 minutes for recovery from anaesthesia. Simulating an 
emergency situation showed that the child can be 
dismounted in less than a minute, giving full access of the 
anaesthesiologist to the child for emergency procedures.  
With this set-up we treated three children (10 months, 5 
years, and 7 months). Treatment was tolerated well. With 
the frontal irradiation approach we can use the benefits of 
a dedicated eye beam line: sharp lateral penumbra and 
sharp distal fall-off, enabling us to spare the bones of the 
skull completely.  
SUMMARY 
ISL fulfilled its duty to the users till the very end. All 
planned research activities have been finished. A very 
fruitful phase of research using fast ions was terminated. 
We thank our users for fascinating experiments and the 
ISL accelerator crew for their efforts. By the end of 2006 
the ISL as a multi-purpose accelerator facility was closed. 
Therefore, with the beginning of 2007, the proton therapy 
was reorganised: the Charité is in charge for the therapy, 
the Helmholtz-Zentrum Berlin is in charge for delivering 
the beam.  
We have now experienced the first three years under the 
new boundary conditions; treating more than 600 patients 
in that time. The conversion process is not yet finished. 
The accelerator operation went quite smoothly. We will 
continue to provide unique therapeutic possibilities for the 
patients in Germany. 
This activity is based upon 10 years of accelerator 
development and common R&D of the ISL and the Eye 
Clinic of the Benjamin Franklin University Hospital 
within the Charité. The joined effort created Germany's 
only facility for this kind of therapy. In spite of major 
structural changes we could keep a high quality standard 
and even increased the number of treated patients. Proton 
therapy of ocular tumours for very young children under 
general anaesthesia on a horizontal eye beam line is 
feasible. The neighbouring bones of orbit and skull are 
kept free of irradiation. 
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